FDA Reviewers Recommend Approval of Bayer AG Hypertension Drug But at Lower Doses
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Bayer AG's experimental drug to treat two types of pulmonary hypertension worked well in clinical trials and should be approved, but at lower doses than those proposed by the company, according to medical reviewers at the U.S. Food and Drug Administration. The reviewers posted their report on the agency's website in preparation for a meeting on Tuesday of outside medical experts who will make their own recommendation on whether the FDA should approve the drug, riociguat. If approved, the drug would be sold under the brand name Adempas. It is designed to improve the ability of patients with chronic thromboembolic pulmonary hypertension to exercise.
Help employers find you! Check out all the jobs and post your resume.
Bayer AG's experimental drug to treat two types of pulmonary hypertension worked well in clinical trials and should be approved, but at lower doses than those proposed by the company, according to medical reviewers at the U.S. Food and Drug Administration. The reviewers posted their report on the agency's website in preparation for a meeting on Tuesday of outside medical experts who will make their own recommendation on whether the FDA should approve the drug, riociguat. If approved, the drug would be sold under the brand name Adempas. It is designed to improve the ability of patients with chronic thromboembolic pulmonary hypertension to exercise.
Help employers find you! Check out all the jobs and post your resume.